Polyclonal spread of blaCTX-M-15 through high-risk clones of Escherichia coli at a tertiary hospital in Ethiopia

Sewunet, Tsegaye; Asrat, Daniel; Woldeamanuel, Yimtubezinash; Ny, Sofia; Westerlund, Fredrik; Aseffa, Abraham; Giske, Christian G.

doi:10.1016/j.jgar.2021.09.017

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This gene was the dominant genotype among the ESBL-positive isolates in our study. This is in line with the report from Ethiopia, where a study investigated the genome-based epidemiology of ESBL-producing E. coli among patients seeking medical care at a tertiary hospital in Jimma [45] and a study on the fecal carriage of ESBL-producing Enterobacteriaceae in young children in Tanzania [46]. In addition, the predominance of bla CTX-M-15 in E. coli was also found in bacteriemic patients in two teaching hospitals in Bamako, Mali [47].…”

Section: Mdr and Esbl-producing E Coli Among Studied Isolatessupporting

confidence: 85%

Antimicrobial Susceptibility and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia

Wolde,

Eguale,

Alemayehu

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Antimicrobial resistance of Escherichia coli is a growing problem in both developed and developing countries. This study aimed to investigate the phenotypic antimicrobial resistance of E. coli isolates (n = 260) isolated from the stool specimen of patients attending public health facilities in Addis Ababa and Hossana. This study also aimed to characterize phenotypically confirmed extended-spectrum beta-lactamase (ESBL)-producing E. coli isolates (n = 22) using whole-genome sequencing. Resistance to 18 different antimicrobials was assessed using the disc diffusion method according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The highest resistance rate among the E. coli isolates was found for ampicillin (52.7%), followed by trimethoprim-sulfamethoxazole (29.6%). Of all isolates, 50 (19.2%) were multidrug-resistant and 22 (8.5%) were ESBL producers. ESBL genes were detected in 94.7% of the sequenced E. coli isolates, and multiple β-lactamase genes were detected in 57.9% of the isolates. The predominant ESBL gene identified was blaCTX-M-15 (78.9%). The blaTEM-1B gene was detected in combination with other ESBL genes in 57.9% of the isolates, while only one of the sequenced isolates contained the blaTEM-1B gene alone. The blaCTX-M-3 gene was detected in three isolates. The genes blaCTX-M-15 and blaTEM-1B as well as blaCTX-M-15 and blaTEM-169 were confirmed to coexist in 52.6% and 10.5% of the sequenced E. coli isolates, respectively. In addition, blaOXA-1 was identified together with blaCTX-M-15 and blaTEM-1B in one isolate, and in one isolate, blaTEM-169 together with blaCTX-M-15 and blaTEM-1B was found. The results obtained show that measures need to be taken to reduce the spread of drug resistance and ensure the long-term use of available antimicrobials.

show abstract

Section: Mdr and Esbl-producing E Coli Among Studied Isolatessupporting

confidence: 85%

Antimicrobial Susceptibility and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia

Wolde,

Eguale,

Alemayehu

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Previous studies conducted in the same study area have reported a high prevalence of ESBL-producing bacteria and carbapenem-resistant strains among Gram-negative bacteria isolated from clinical samples [13][14][15][16][17]. The prevalence rates for ESBL producers range from 50 to 80%, while carbapenem-resistant strains range from 10 to 20% [13][14][15][16][17]. Notably, ESBL production is commonly observed in bacteria such as E. coli, K. pneumoniae, K. variicola, E. cloacae, and many others [14,15,17].…”

Section: Introductionmentioning

confidence: 90%

“…The prevalence rates for ESBL producers range from 50 to 80%, while carbapenem-resistant strains range from 10 to 20% [13][14][15][16][17]. Notably, ESBL production is commonly observed in bacteria such as E. coli, K. pneumoniae, K. variicola, E. cloacae, and many others [14,15,17]. Similarly, the emergence of carbapenem resistance is frequently detected in Gram-negative bacteria such as A. baumannii, P. aeruginosa, E. coli, and K. pneumoniae [16,17].…”

Section: Introductionmentioning

confidence: 99%

Hospital Wastes as Potential Sources for Multi-Drug-Resistant ESBL-Producing Bacteria at a Tertiary Hospital in Ethiopia

Gashaw,

Gudina,

Tadesse

et al. 2024

Antibiotics

View full text Add to dashboard Cite

The hospital environment is increasingly becoming an important reservoir for multi-drug-resistant (MDR) Gram-negative bacteria, posing serious challenges to efforts to combat antimicrobial resistance (AMR). This study aimed to investigate the role of hospital waste as a potential source of MDR ESBL-producing bacteria. Samples were collected from multiple sources within a hospital and its vicinity, including surface swabs, houseflies, and sewage samples. The samples were subsequently processed in a microbiology laboratory to identify potential pathogenic bacteria and confirmed using MALDI-TOF MS. Bacteria were isolated from 87% of samples, with the predominant isolates being E. coli (30.5%), Klebsiella spp. (12.4%), Providencia spp. (12.4%), and Proteus spp. (11.9%). According to the double disc synergy test (DDST) analysis, nearly half (49.2%) of the bacteria were identified as ESBL producers. However, despite exhibiting complete resistance to beta-lactam antibiotics, 11.8% of them did not test positive for ESBL production. The characterization of E. coli revealed that 30.6% and 5.6% of them carried blaCTX-M group 1 type-15 and blaNDM genes, respectively. This finding emphasizes the importance of proper hospital sanitation and waste management practices to mitigate the spread of AMR within the healthcare setting and safeguard the health of both patients and the wider community.

show abstract

“…Despite studies that investigated CTX-M-producing E. coli in diarrhoea cases in Africa [ 12 , 23 , 24 , 25 , 26 ], there is a dearth of information on beta-lactamase (CTX-M) resistance in E. coli associated with diarrhoea in young children. In addition, detailed genomic studies using sequencing techniques to uncover the epidemiology of high-risk clones such as sequence type 131 (ST131), which are associated with the dissemination of CTX-M genes are limited in Africa [ 27 ]. Previous studies that have been conducted in children investigated CTX-M-producing E. coli recovered from urinary infections [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of Cefotaxime-Hydrolysing β-Lactamase-Producing Escherichia coli in Children with Diarrhoea Reported Globally between 2012 and 2022

Karambwe,

Traoré,

Potgieter

2024

Microorganisms

View full text Add to dashboard Cite

The global spread of cefotaxime-hydrolysing β-lactamase (CTX-M)-producing Escherichia coli (E. coli) and its associated impact on paediatric diarrhoeal treatment and management has become a public health concern. This review assessed surveillance studies on CTX-M-producing E. coli associated with diarrhoea in children published between 2012 and 2022 globally. A total of thirty-eight studies were included for data analysis, categorised into continental regions, and tabulated. The majority (68%) of studies were conducted in Asian countries while few studies were conducted in Europe (11%) and Africa (18%), respectively. On the African continent, the majority (11%) of studies were conducted in Northern Africa while no studies were reported in East Africa. On the American continent, 3% of the studies were reported from South America. The studies included were classified into diarrheagenic E. coli (74%; 28/38) and faecal carriage (26%; 10/38). Of all the E. coli pathotypes associated with CTX-M production, EPEC was frequently reported. The prevalence of CTX-M-producing E. coli including the CTX-M-15-producing variants ranged between 1% and 94%. About 37% of the studies generalised the report as blaCTX-M-positive E. coli. The use of sequencing in characterising the CTX-M-producing E. coli was reported in only 32% of all the studies. This review provides information on the epidemiology of CTX-M-15-producing E. coli in paediatric diarrhoea and the extent to which surveillance is being performed. This is relevant in informing clinical practice for the management of diarrhoea as well as the design of future surveillance studies.

show abstract

Polyclonal spread of blaCTX-M-15 through high-risk clones of Escherichia coli at a tertiary hospital in Ethiopia

Cited by 3 publications

References 39 publications

Antimicrobial Susceptibility and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia

Antimicrobial Susceptibility and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia

Hospital Wastes as Potential Sources for Multi-Drug-Resistant ESBL-Producing Bacteria at a Tertiary Hospital in Ethiopia

Epidemiology of Cefotaxime-Hydrolysing β-Lactamase-Producing Escherichia coli in Children with Diarrhoea Reported Globally between 2012 and 2022

Contact Info

Product

Resources

About